Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to $935198.0.

  • BioRestorative Therapies' Non-Current Assets fell 1214.77% to $935198.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year decrease of 1355.36%. This contributed to the annual value of $1.1 million for FY2024, which is 701.08% down from last year.
  • BioRestorative Therapies' Non-Current Assets amounted to $935198.0 in Q3 2025, which was down 1214.77% from $918752.0 recorded in Q2 2025.
  • BioRestorative Therapies' Non-Current Assets' 5-year high stood at $1.3 million during Q4 2022, with a 5-year trough of $918752.0 in Q2 2025.
  • Moreover, its 5-year median value for Non-Current Assets was $1.1 million (2021), whereas its average is $1.1 million.
  • Per our database at Business Quant, BioRestorative Therapies' Non-Current Assets surged by 3253.68% in 2022 and then crashed by 1775.33% in 2025.
  • Quarter analysis of 5 years shows BioRestorative Therapies' Non-Current Assets stood at $985538.0 in 2021, then soared by 32.54% to $1.3 million in 2022, then fell by 6.51% to $1.2 million in 2023, then decreased by 7.01% to $1.1 million in 2024, then dropped by 17.65% to $935198.0 in 2025.
  • Its last three reported values are $935198.0 in Q3 2025, $918752.0 for Q2 2025, and $971500.0 during Q1 2025.